Melanoma-associated antigens and co-stimulatory molecules (transgene-expressed) (MAA/Co-stim transgenes)

Melanoma-associated antigens and co-stimulatory molecules expressed from transgenes refers to a multi-component immunotherapy strategy rather than a single molecular target. This approach involves the use of genetic vectors, such as viral (e.g., ALVAC, Adenovirus) or plasmid DNA, to deliver genes encoding specific tumor antigens like gp100, MART-1, or Tyrosinase alongside co-stimulatory molecules such as B7-1 (CD80) or B7-2 (CD86) [1, 2]. The biological intent is to provide both the primary signal (antigen recognition via MHC) and the essential secondary signal (co-stimulation via CD28) required for the robust activation of cytotoxic T lymphocytes (CTLs) [3]. In many malignancies, the tumor microenvironment lacks these co-stimulatory signals, leading to T-cell anergy; thus, transgene expression aims to artificially restore these signals to trigger a systemic anti-tumor immune response [1, 4]. This strategy is primarily employed in the development of therapeutic cancer vaccines and oncolytic viral therapies for advanced melanoma, often evaluated in combination with immune checkpoint inhibitors [2, 5]. Sources: [1] Restifo, N. P., et al. (2012) Nature Reviews Immunology; [2] Kaufman, H. L., et al. (2004) Clinical Cancer Research; [3] Rosenberg, S. A. (2001) Nature; [4] NIH National Cancer Institute Drug Dictionary; [5] Larocca, C. & Schlom, J. (2011) Cancer Journal.

Other names

Tumor-associated antigens with co-stimulatory signalsRecombinant viral vaccine antigensMAA/B7-1 transgene complexGenetically engineered melanoma antigens

Induction of tumor-specific T-cell responses through the simultaneous presentation of tumor-associated antigens and co-stimulatory signals to overcome tumor-induced immunosuppression and T-cell anergy.